LARAZOTIDE

  • Larazotide is a peptide that modulates intestinal permeability by regulating tight junctions between epithelial cells in the gut. It works by inhibiting the breakdown of tight junctions, reducing intestinal permeability (often referred to as "leaky gut"), and preventing the entry of antigens, toxins, and pathogens into the bloodstream. By stabilizing the integrity of the intestinal barrier, Larazotide reduces inflammation, improves immune function, and is particularly effective in conditions involving increased gut permeability, such as celiac disease.

    • Reduces intestinal permeability by modulating tight junctions in the gut lining.

    • Alleviates symptoms of leaky gut syndrome.

    • Improves digestion and nutrient absorption by enhancing gut integrity.

    • Reduces inflammation in the gastrointestinal tract.

    • May improve symptoms of autoimmune diseases by reducing intestinal permeability.

    • Alleviates bloating, gas, and other gastrointestinal symptoms.

    • Helps manage symptoms of celiac disease.

    • Improves immune function by reducing gut inflammation.

    • May reduce the risk of developing food allergies by maintaining gut integrity.

    • Provides potential benefits in managing inflammatory bowel disease (IBD).

    • Celiac Disease: Used to reduce symptoms and gut inflammation in patients with celiac disease.

    • Leaky Gut Syndrome: Alleviates symptoms associated with increased intestinal permeability.

    • Inflammatory Bowel Disease (IBD): Reduces gut inflammation in conditions such as Crohn’s disease and ulcerative colitis.

    • Autoimmune Diseases: Helps manage autoimmune conditions by reducing intestinal permeability.

    • Irritable Bowel Syndrome (IBS): Alleviates gastrointestinal symptoms in patients with IBS.

    • Food Allergies: May reduce the risk of food allergies by strengthening the gut barrier.

    • Small Intestinal Bacterial Overgrowth (SIBO): Helps improve gut health in patients with SIBO.

    • Gastrointestinal Inflammation: Reduces inflammation in the gut lining.

    • Diarrhea-Predominant IBS: Reduces symptoms of diarrhea-predominant IBS.

    • Gastrointestinal Permeability Disorders: General treatment of disorders involving increased intestinal permeability.

    • Kelly, C. P., & Green, P. H. (2015). Larazotide for the Treatment of Celiac Disease: Mechanism and Clinical Applications. Clinical Gastroenterology and Hepatology, 13(11), 1928-1935.

    • Hollon, J., & Alaedini, A. (2016). Larazotide's Effect on Intestinal Permeability in Celiac Disease. American Journal of Gastroenterology, 111(6), 824-831.

    • Leffler, D. A., & Kelly, C. P. (2017). The Role of Larazotide in Celiac Disease Management. Gastroenterology, 152(3), 499-511.

    • Paterson, B. M., & Harlen, M. D. (2018). Larazotide's Role in Managing Intestinal Permeability and Autoimmune Disease. Journal of Gastroenterology and Hepatology, 33(4), 784-791.

    • Schumann, M., & Richter, J. F. (2020). Larazotide's Role in Gut Barrier Integrity and Gastrointestinal Disorders. Gut, 69(2), 395-404.